ArticleApplied microbiology and biotechnology2026
Genomic and structural insights into the in vivo development of cefiderocol resistance in Klebsiella pneumoniae.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol is a newly developed siderophore-conjugated cephalosporin specifically designed to overcome multidrug-resistant (MDR) Gram-negative bacilli. Nevertheless, reduced susceptibility and resistance to cefiderocol has increasingly been reported, especially derived from alterations in iron transport systems and plasmid-mediated determinants and the expression of structural variants of β-lactamases. Moreover, cefiderocol resistance derived from target alteration remains insufficiently defined. This work aimed to characterize the genomic and structural basis of cefiderocol resistance emerging in vivo during therapy in Klebsiella pneumoniae. Comparative genomics revealed conserved plasmid architecture and no acquisition of novel β-lactamases or iron-uptake determinants. Eighty-two chromosomal variants were identified, among which a missense substitution in ftsI (FtsI G306V), located adjacent to the catalytic serine (S307) of PBP3, emerged as a plausible resistance determinant. Structural modelling suggests that the G306V substitution introduces a significant side-chain volumetric increase, resulting in locally increased steric hindrance within the active-site, possibly impairing cefiderocol interaction with its target. The absence of canonical iron-transport alterations further distinguishes this case from the predominant mechanism described in global molecular epidemiology studies. Large-scale genomic screening revealed a very low prevalence of substitutions affecting ftsI, including in resistance isolates, although possible clonal expansion cannot be ruled out. Our findings align with the broader epidemiological landscape in which cefiderocol resistance is heterogeneous and flexible. Therefore, incorporating analysis of ftsI variants within or proximal to the active-site into genomic surveillance frameworks could improve resistance detection to this last-resort antibiotic. KEY POINTS: • Resistance occurred without alterations in iron-uptake systems or siderophore pathways. • Mutations in FtsI (G306V) and AcrR (E91K) were identified as key candidates. • FtsI G306V is rare across cefiderocol resistant and global K. pneumoniae genomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.